PMID- 28438462
OWN - NLM
STAT- MEDLINE
DCOM- 20171122
LR  - 20171128
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 23
IP  - 7
DP  - 2017 Jul
TI  - Comparison of interferon-gamma release assays, QuantiFERON TB-GIT and T-Spot.TB, in 
      renal transplantation.
PG  - 468-473
LID - S1341-321X(17)30087-9 [pii]
LID - 10.1016/j.jiac.2017.04.002 [doi]
AB  - Renal transplant recipients are at increased risk of reactivating latent 
      tuberculosis infection (LTBI) and progressing to active tuberculosis (TB). This 
      study was conducted in National hospital for tuberculosis and renal 
      transplantation (RT) in Japan. The purpose is to compare two interferon-gamma release 
      assays (IGRAs), QuantiFERON((R))-TB Gold in Tube (QFT) and T-SPOT((R)).TB (TSPOT), in 
      patients after renal transplantation for detecting latent TB infection (LTBI). 
      Total 92 renal transplant recipients (median age 46 years, range 17-75) were 
      prospectively enrolled, and QFT and TSPOT were concurrently examined. Total 
      subjects were 92 patients (median age 46 years, range 17-75). The positive rate 
      in QFT and TSPOT were 6.5% (95% confidence interval (CI) 3.0-13.5) and 2.2% (95% 
      CI 1.0-7.6), respectively. There was a significant difference in IGRAs positivity 
      (P < 0.05). The negative rate in QFT and TSPOT were 91.3% (95% CI 83.8-95.5) and 
      95.7% (95% CI 89.3-98.3), respectively. There was no significant difference in 
      IGRAs negativity. No patients among either IGRAs negative patients developed 
      active TB during median follow-up of 994 days. Neither QFT nor TSPOT reaches 
      estimated TB infection rate in Japan, especially elderly recipients aged 60 
      year-old or more. Therefore, both IGRAs might underestimate LTBI owing to immune 
      suppressive therapy and aging. Physicians for renal transplantation need to 
      understand the characteristics of both IGRAs and pay attention to the possibility 
      of developing active TB even in patients of negative IGRAs results.
CI  - Copyright (c) 2017 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Ishikawa, Satoru
AU  - Ishikawa S
AD  - Department of Respiratory Medicine, National Hospital Organization Chiba-East 
      Hospital, Japan.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Department of Respiratory Medicine, National Hospital Organization Chiba-East 
      Hospital, Japan; Division of Infection Control, Chiba University Hospital, Japan. 
      Electronic address: hide306@gmail.com.
FAU - Akutsu, Naotake
AU  - Akutsu N
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Tsuyuzaki, Mizue
AU  - Tsuyuzaki M
AD  - Chiba Foundation for Health Promotion and Disease Prevention, Japan.
FAU - Aoyama, Hiromichi
AU  - Aoyama H
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Hasegawa, Masayuki
AU  - Hasegawa M
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Otsuki, Kazunori
AU  - Otsuki K
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Maruyama, Michihiro
AU  - Maruyama M
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Saigo, Kenichi
AU  - Saigo K
AD  - Department of Surgery, National Hospital Organization Chiba-East Hospital, Japan.
FAU - Suzuki, Kiminori
AU  - Suzuki K
AD  - Chiba Foundation for Health Promotion and Disease Prevention, Japan.
FAU - Yamagishi, Fumio
AU  - Yamagishi F
AD  - Department of Respiratory Medicine, National Hospital Organization Chiba-East 
      Hospital, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170421
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Immunocompromised Host
MH  - Interferon-gamma/immunology/metabolism
MH  - Interferon-gamma Release Tests/*methods/*standards
MH  - *Kidney Transplantation
MH  - Latent Tuberculosis/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Young Adult
OTO - NOTNLM
OT  - Immune suppressive condition
OT  - Interferon-gamma release assay
OT  - Latent tuberculosis infection
OT  - Renal transplantation
EDAT- 2017/04/26 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/04/26 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/03/17 00:00 [revised]
PHST- 2017/04/03 00:00 [accepted]
PHST- 2017/04/26 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/04/26 06:00 [entrez]
AID - S1341-321X(17)30087-9 [pii]
AID - 10.1016/j.jiac.2017.04.002 [doi]
PST - ppublish
SO  - J Infect Chemother. 2017 Jul;23(7):468-473. doi: 10.1016/j.jiac.2017.04.002. Epub 
      2017 Apr 21.